Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Point-of-care PSA testing: an evaluation of PSAwatch

Prostate Cancer and Prostatic Diseases volume 10, pages 270–273 (2007)Cite this article

Abstract

We present a new quantitative prostate-specific antigen (PSA) assay using a portable, point-of-care test (PSAwatch) and reader system (BioScan) for measuring PSA concentrations in the range from 0.5 to ⩽25 μg/l. Blood samples from patients (n=199) were submitted for laboratory PSA and also evaluated using PSAwatch and the BioScan system. PSA concentrations in 188 men were ⩽25 μg/l and studied. Correlation between the two methods was good (R2=0.88) with a standard error of 1.588. The regression line had a bias of −0.02 at the concentration of 4.00 μg/l. This is the first report of a quantitative, portable, point-of-care PSA test and reader system. PSAwatch may reduce the number of hospital visits for patients with prostate disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Ablin RJ, Bronson P, Soanes WA, Witebsky E . Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 1970; 104: 1329–1339.

    CAS  PubMed  Google Scholar 

  2. Wang MC, Valenzuela LA, Murphy GP, Chu TM . Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–163.

    CAS  PubMed  Google Scholar 

  3. Polascik TJ, Oesterling JE, Partin AW . Prostate specific antigen: a decade of discovery what we have learned and where we are going. J Urol 1999; 162: 293–306.

    Article  CAS  PubMed  Google Scholar 

  4. Roehrborn CG, Malice M, Cook TJ, Girman CJ . Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210–216.

    Article  CAS  PubMed  Google Scholar 

  5. Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM . Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 2005; 65: 300–305.

    Article  CAS  PubMed  Google Scholar 

  6. D'Ambrosio G, Samani F, Cancian M, De Mola C . Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 2004; 13: 383–386.

    Article  CAS  PubMed  Google Scholar 

  7. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956–960.

    Article  PubMed  Google Scholar 

  8. AOU. Action On Urology Good Practice Guide – Outcomes from 32 Action On Urology Sites. NHS Modernisation Agency, p 31. March 2005.

  9. Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R et al. Prostate cancer patients' support and psychological care needs: survey from a non-surgical oncology clinic. Psycho-oncology 2003; 12: 769–783.

    Article  PubMed  Google Scholar 

  10. Milford Ward A, Catto JWF, Hamdy FC . Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001; 38: 633–651.

    Article  Google Scholar 

  11. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH . Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001; 88: 545–550.

    Article  CAS  PubMed  Google Scholar 

  12. R Development Core Team 2006. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN: 3-900051-07-0, URL: http://www.R-project.org.

  13. AOU. Action On Urology Good Practice Guide – Outcomes from 32 Action On Urology Sites. NHS Modernisation Agency, p 4. March 2005.

  14. AOU. Action On Urology Good Practice Guide – Outcomes from 32 Action On Urology Sites. NHS Modernisation Agency, p 6. March 2005.

  15. Cancer Services Collaborative. Improvement Partnership. http://www.modern.nhs.uk/cancer.

  16. Singh R, Cahill D, Popert R, O'Brien TS . Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int 2003; 92: 932–935.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the nursing staff in the Urology clinic at Wexham Park Hospital and the Bridge Clinic for their support with this project. This work was financially supported by Mediwatch Plc. Mr Omer Karim and Mr Mark Emberton are Nonexecutive Directors of Mediwatch Plc.

Author information

Authors and Affiliations

  1. Department of Urology, Wexham Park Hospital, Slough, UK

    O Karim & A Rao

  2. Mediwatch Plc, Swift House, Rugby, UK

    O Karim, M Emberton, D Cochrane, M Partridge, P Edwards & I Davidson

  3. Department of Urology, The Institute of Urology, University College London, London, UK

    M Emberton

  4. Department of Biochemistry, Wexham Park Hospital, Slough, UK

    I Walker

Authors
  1. O Karim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Emberton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Cochrane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Partridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O Karim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karim, O., Rao, A., Emberton, M. et al. Point-of-care PSA testing: an evaluation of PSAwatch. Prostate Cancer Prostatic Dis 10, 270–273 (2007). https://doi.org/10.1038/sj.pcan.4500962

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500962

Keywords

This article is cited by

Search

Advanced search

Quick links